Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes
- PMID: 16105859
- DOI: 10.1152/ajpendo.00529.2004
Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes
Abstract
To assess mechanisms for postprandial hyperglycemia, we used a triple-isotope technique ([\3-(3)H]glucose and [(14)C]bicarbonate and oral [6,6-dideutero]glucose iv) and indirect calorimetry to compare components of glucose release and pathways for glucose disposal in 26 subjects with type 2 diabetes and 15 age-, weight-, and sex-matched normal volunteers after a standard meal. The results were as follows: 1) diabetic subjects had greater postprandial glucose release (P<0.001) because of both increased endogenous and meal-glucose release; 2) the greater endogenous glucose release (P<0.001) was due to increased gluconeogenesis (P<0.001) and glycogenolysis (P=0.01); 3) overall tissue glucose uptake, glycolysis, and storage were comparable in both groups (P>0.3); 4) glucose clearance (P<0.001) and oxidation (P=0.004) were reduced, whereas nonoxidative glycolysis was increased (P=0.04); and 5) net splanchnic glucose storage was reduced by approximately 45% (P=0.008) because of increased glycogen cycling (P=0.03). Thus in type 2 diabetes, postprandial hyperglycemia is primarily due to increased glucose release; hyperglycemia overcomes the effects of impaired insulin secretion and sensitivity on glucose transport, but intracellular defects persist so that pathways of glucose metabolism are abnormal and glucose is shunted away from normal sites of storage (e.g., liver and muscle) into other tissues.
Similar articles
-
Pathways for glucose disposal after meal ingestion in humans.Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E716-25. doi: 10.1152/ajpendo.00365.2002. Epub 2002 Dec 10. Am J Physiol Endocrinol Metab. 2003. PMID: 12475753
-
Metabolic fate of plasma glucose during hyperglycemia in impaired glucose tolerance: evidence for further early defects in the pathogenesis of type 2 diabetes.Am J Physiol Endocrinol Metab. 2009 Mar;296(3):E440-4. doi: 10.1152/ajpendo.90505.2008. Epub 2009 Jan 13. Am J Physiol Endocrinol Metab. 2009. PMID: 19141691
-
Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes.Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1049-56. doi: 10.1152/ajpendo.00041.2004. Epub 2004 Aug 10. Am J Physiol Endocrinol Metab. 2004. PMID: 15304374
-
Inhibition of glucagon secretion.Adv Pharmacol. 2005;52:151-71. doi: 10.1016/S1054-3589(05)52008-8. Adv Pharmacol. 2005. PMID: 16492545 Review.
-
[Physiopathological fundamentals of type 2 diabetes].Rev Prat. 1999 Jan 1;49(1):22-9. Rev Prat. 1999. PMID: 9926712 Review. French.
Cited by
-
Insulin and Glucagon: Partners for Life.Endocrinology. 2017 Apr 1;158(4):696-701. doi: 10.1210/en.2016-1748. Endocrinology. 2017. PMID: 28323959 Free PMC article. Review.
-
A Single Day of Excessive Dietary Fat Intake Reduces Whole-Body Insulin Sensitivity: The Metabolic Consequence of Binge Eating.Nutrients. 2017 Jul 29;9(8):818. doi: 10.3390/nu9080818. Nutrients. 2017. PMID: 28758920 Free PMC article. Clinical Trial.
-
Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.Endocrinology. 2012 Mar;153(3):1039-48. doi: 10.1210/en.2011-1499. Epub 2011 Dec 13. Endocrinology. 2012. PMID: 22166985 Free PMC article. Review.
-
Potential Bioactive Compounds from Seaweed for Diabetes Management.Mar Drugs. 2015 Aug 21;13(8):5447-91. doi: 10.3390/md13085447. Mar Drugs. 2015. PMID: 26308010 Free PMC article. Review.
-
Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration.Metabolites. 2023 Apr 18;13(4):572. doi: 10.3390/metabo13040572. Metabolites. 2023. PMID: 37110230 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical